Unicycive Therapeutics, Inc. Share Price
NASDAQ: UNCY | Micro CapUnicycive Therapeutics, Inc. Stock Performance
Open $5.13 | Prev. Close $5.04 | Circuit Range N/A |
Day Range $5.05 - $5.18 | Year Range $3.72 - $8.74 | Volume 31,910 |
Average Traded $5.09 |
Unicycive Therapeutics, Inc. Share Price Today
As of 10 August 2026, Unicycive Therapeutics, Inc.'s share price is $5.07. The stock opened at $5.13, compared to its previous close of $5.04. During today's trading session, Unicycive Therapeutics, Inc.'s share price traded between $5.05 and $5.18, with an average price of $5.12. Over the past 52 weeks, the stock has recorded a high of $8.74 and a low of $3.72. In terms of performance, Unicycive Therapeutics, Inc.'s share price has declined by 26.95% over the last six months and is up 20.43% on a year-on-year basis.
Unicycive Therapeutics, Inc. Share Price Chart
Unicycive Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $80.55M | PE Ratio (TTM) -3.04 | Dividend Yield N/A |
EPS (TTM) $-1.67 | Revenue (TTM) $675000.00 | Return On Equity (TTM) -87.94% |
Profit Margin -3934.07% | Debt to Equity 0.63 | Quarterly Earnings Growth YoY -311.86% |
Unicycive Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Unicycive Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.00 | $5.06 | +0.90% |
Jul 2026 | $4.58 | $5.01 | +6.03% |
Jun 2026 | $7.50 | $4.73 | -35.73% |
May 2026 | $7.72 | $7.36 | -3.92% |
Apr 2026 | $6.78 | $7.66 | +16.50% |
Mar 2026 | $6.70 | $6.58 | -5.26% |
Feb 2026 | $6.00 | $6.94 | +16.54% |
Jan 2026 | $5.79 | $5.96 | +3.21% |
Dec 2025 | $6.42 | $5.77 | -10.68% |
Nov 2025 | $4.74 | $6.46 | +36.29% |
Oct 2025 | $4.20 | $4.74 | +9.22% |
Sep 2025 | $4.11 | $4.34 | +3.09% |
UNCY Share Price FAQs
What is Unicycive Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Unicycive Therapeutics, Inc. stock?
What is UNCY's market capitalisation today?
What is UNCY's net income for the last quarter?
What is the 5 year returns of UNCY?
What is the high & low stock price of UNCY today?
Can I buy UNCY shares in India?